Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • United Health Group...

    United Health Group OptumRx accused of drug overcharges

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-19T09:00:00+05:30  |  Updated On 19 March 2019 9:00 AM IST
    United Health Group OptumRx accused of drug overcharges

    Yost accused OptumRx of failing for nearly three years to provide agreed-upon discounts for generic drugs purchased by injured workers submitting claims to the Ohio Bureau of Workers' Compensation.


    U.S: Ohio's attorney general on Monday said he had filed a lawsuit against United Health Group Inc's OptumRx unit, saying the pharmacy benefit manager had overcharged the state nearly $16 million for prescription drugs.


    Ohio Attorney General Dave Yost's lawsuit followed a probe into the extent pharmacy benefit managers (PBMs) like OptumRx had engaged in pricing practices that resulted in the state overpaying for drugs for people covered by state health programs.


    The probe, begun under Gov. Mike DeWine before he left his position of attorney general earlier this year, came amid public concerns about skyrocketing drug prices and the role that PBMs as pharmacy middlemen play in contributing to the costs.


    Yost accused OptumRx of failing for nearly three years to provide agreed-upon discounts for generic drugs purchased by injured workers submitting claims to the Ohio Bureau of Workers' Compensation.


    "Our review of PBM practices throughout state government is still ongoing," Yost said in a statement. "These are the first raindrops, but there's a storm a-comin'."


    The lawsuit, filed on Friday in Franklin County Court of Common Pleas, seeks at least $15 million in compensatory damages and $15 million in punitive damages.


    OptumRx did not immediately respond to a request for comment. It has previously said the state's overcharging claims are "without merit."


    PBMs negotiate drug prices for employers and health plans. They typically demand steep discounts off the drugmakers' list prices for medicines in exchange for including their products on the PBMs' preferred formularies, or lists of drugs approved for reimbursement.


    In Ohio, the Bureau of Workers' Compensation and the state's Medicaid program contract with PBMs to manage drug prescriptions for the agencies' clients.


    Yost, who was elected attorney general in November, previously served as the state's auditor.


    In that role, he released a report in August that found PBMs had charged the state's Medicaid program an average "spread" of 31 per cent for generic drugs, billing $208 million more from April 2017 through March 2018 than it cost to reimburse pharmacies.


    OptumRx is the PBM for one of Ohio's five Medicaid managed-care plans. CVS Health's CVS Caremark unit acts as the PBM for the other four. The two companies administer $2.5 billion in annual Medicaid drug spending for Ohio.


    OptumRx had also contracted with the workers' compensation agency. But last year, the agency announced it had hired another company to manage its pharmaceutical program for injured workers amid claims OptumRx overcharged it.


    Also Read: NPPA revises ceiling prices of 14 drug formulations including Injections, Inhalators; Details

    CVS CaremarkCVS HealthDave Yost'drug pricedrugsgeneric drugshealthhealth caremedicalmedicineMike DeWineohioOhio's attorneyOptum RxOptumRxpharmaceuticalpharmacy benefit managersreimbursementUnited HealthUnited Health Group
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok